Страна: Канада
Язык: английский
Источник: Health Canada
FAMPRIDINE
TARO PHARMACEUTICALS INC
N07XX07
FAMPRIDINE
10MG
TABLET (EXTENDED-RELEASE)
FAMPRIDINE 10MG
ORAL
(2X14)/(4X14)/28/56
Prescription
OTHER MISCELLANEOUS THERAPEUTIC AGENTS
Active ingredient group (AIG) number: 0153090001; AHFS:
APPROVED
2020-05-15
_Page 1 of 31_ PRODUCT MONOGRAPH Pr Taro-Fampridine Fampridine Sustained Release Tablet 10 mg Potassium Channel Blocker Taro Pharmaceuticals Inc. Date of Preparation: November 05, 2018 130 East Drive, Brampton Ontario L6T 1C1 Submission Control No: 212539 _Page 2 of 31_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION................................................................3 SUMMARY PRODUCT INFORMATION ....................................................................................3 INDICATIONS AND CLINICAL USE ..........................................................................................3 CONTRAINDICATIONS ...............................................................................................................3 WARNINGS AND PRECAUTIONS ..............................................................................................4 ADVERSE REACTIONS................................................................................................................9 DRUG INTERACTIONS ..............................................................................................................14 DOSAGE AND ADMINISTRATION ..........................................................................................15 OVERDOSAGE ............................................................................................................................16 ACTION AND CLINICAL PHARMACOLOGY ........................................................................17 STORAGE AND STABILITY ......................................................................................................19 SPECIAL HANDLING INSTRUCTIONS ...................................................................................19 DOSAGE FORMS, COMPOSITION AND PACKAGING .........................................................19 PART II: SCIENTIFIC INFORMATION ....................................................................................20 PHARMACEUTICAL INFORMATION.................................................... Прочитать полный документ